Overview:

Summary

Pharmaceutical and healthcare report offering, “Bronchitis - Drug Pipeline Analysis and Market Forecasts to 2016” is an essential source of information and analysis on the global bronchitis market. The report identifies the key trends shaping and driving the global bronchitis market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global bronchitis sector.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GlobalData’s team of industry experts.The global bronchitis market was valued at $482m in 2009 and is forecast to grow by 3.7% annually for the next seven years. The typical form of bronchitis is self-limited. The bronchitis market is characterized by many generics and OTC. The NSAIDS, cough suppressants and antipyretics are mere supportive therapies. Antibiotics are highly prescribed to treat atypical form of the disease. The increase in the market size is attributed to the increase in incidence and increase in the up take of cost effective drugs

There are 13 molecules in the various phases of the developmental pipeline. Of these, only five are in Phase III and the rest are in the early stages of development. The pipeline consists of no new antibiotics. The antibiotics in the pipeline are generic. Upon approval they will add to the competition. The phase of the pipeline consists of levefloxacin and Merck’s Singulair. Upon approval they are expected to intensify the competition

Scope

The scope of the report includes:

• Annualized global bronchitis market revenues data from 2001 to 2009, forecast for seven years to 2016.

• Geographies covered in this report are the United States (US), the United Kingdom (UK), Italy, Spain, Germany, France, and Japan.

• Pipeline analysis data providing a split across different phases, mechanisms of action being developed and emerging trends. The key classes of mechanism of action include alpha 1 adrenergic receptors agonist, beta (2)-adrenergic agonist,, anti-inflammatory, inhibitor topoisomerase IV DNA gyrase, glucocorticoid agonist leukotriene D4 antagonist and loop diuretic

• Analysis of the current and future market competition in the global bronchitis market. The key market players covered are Merck and Co and Johnson & Johnson Pharmaceutical Research & Development, Pfizer and Merck & Co.

• Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.

• Key topics covered include a strategic competitor assessment, market characterization, unmet needs and implications for the future bronchitis market.

Reasons to buy

The report will enhance your decision making capability in a more rapid and time sensitive manner. It will allow you to:

• Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline.

• Develop business strategies by understanding the trends shaping and driving the global bronchitis market.

• Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global bronchitis market in future.

• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

• What’s the next big thing in the global bronchitis market landscape? - Identify, understand and capitalize.

Companies Mentioned

Merck & Co., Inc
Pfizer Inc.
Abbott Laboratories
Johnson & Johnson

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

2 Global Bronchitis: Market Characterization

2.1 Overview

2.1.1 Treatment Options

2.2 Bronchitis Market Size

2.3 Bronchitis Market Forecast and CAGR

2.4 Drivers and Barriers for the Bronchitis Market

2.4.1 Drivers for the Bronchitis Market

2.4.2 Barriers for the Bronchitis Market

2.5 Opportunity and Unmet Need

2.6 Key Takeaway

3 Global Bronchitis Market: Competitive Assessment

3.1 Overview

3.2 Strategic Competitor Assessment

3.3 Product Profile for the Major Marketed Products in the Bronchitis Market

3.3.1 Antivirals

3.3.2 Antibiotics

3.3.3 Analgesics and NSAID

3.4 Key Takeaway

4 Global Bronchitis Market: Pipeline Assessment

4.1 Overview

4.2 Strategic Pipeline Assessment

4.3 Bronchitis Market - Promising Drugs under Clinical Development

4.4 Product Profiles of the Most Promising Products in Bronchitis Market

4.4.1 Dexamethasone

4.4.2 Levofloxacin

4.4.3 Furosemide

4.4.4 Montelukast sodium

4.5 Bronchitis Market - Clinical Pipeline by Mechanism of Action

4.5.1 Bronchitis Disease - Phase III Clinical Pipeline

4.5.2 Bronchitis Disease - Phase II Clinical Pipeline

4.5.3 Bronchitis - Phase I Clinical Pipeline

4.6 Key Takeaway

5 Global Bronchitis Market: Implications for Future Market Competition

6 Global BMarket: Future Players

6.1 Introduction

6.2 Merck & Co., Inc

6.2.1 Company Overview

6.2.2 Business Description

6.2.3 Respiratory Disease Pipeline Product Portfolio

6.3 Pfizer Inc.

6.3.1 Company Overview

6.3.2 Business Description

6.3.3 Respiratory Disease Pipeline Product Portfolio

6.4 Abbott Laboratories

6.4.1 Company Overview

6.4.2 Business Description

6.4.3 Respiratory Disease Pipeline Product Portfolio

6.5 Johnson & Johnson

6.5.1 Company Overview

6.5.2 Business Description

6.5.3 Respiratory Disease Pipeline Product Portfolio

 

7 Bronchitis disease Market: Appendix

7.1 Definitions

7.2 Acronym

7.3 Research Methodology

7.3.1 Coverage

7.3.2 Secondary Research

7.3.3 Forecasting

7.3.4 Primary Research

7.3.5 Expert Panels

7.4 Contact Us

7.5 Disclaimer

7.6 Sources

1.1 List of Tables

Table 1: Bronchitis, Global, Historical Revenue ($m), 2001-2009

Table 2: Bronchitis, Global, Forecasted Reveune ($m), 2009-2016

Table 3: Major Marketed Products Comparison in Bronchitis Market, 2010

Table 4: Bronchitis Therapeutics - Most Promising Drugs Under Clinical Development, 2010

Table 5: Bronchitis - Phase III Clinical Pipeline, 2010

Table 6: Bronchitis - Phase II Clinical Pipeline, 2010

Table 7: Bronchitis - Phase I Clinical Pipeline, 2010

Table 8: Merck & Co., Inc. - Respiratory Disease Pipeline, 2010

Table 9: Pfizer Inc. - Respiratory Disease Pipeline, 2010

Table 10: Johnson & Johnson - Respiratory Disease Pipeline, 2010

1.2 List of Figures

Figure 1: Bronchitis, Global, Historical Revenue ($m), 2001-2009

Figure 2: Bronchitis Disease, Global, Forecasted Revenue ($m), 2009-2016

Figure 3: Opportunity and Unmet Need in the Bronchitis Disease Market, 2010

Figure 4: Strategic Competitor Assessme0nt, 2010

Figure 5: Pipeline Products by Phase of Development, 2009

Figure 6: Technology Trends Analytics Frame Work, 2010

Figure 7: Technology Trends Analytics Frame Work - Description, 2010

Figure 8: Bronchitis Market - Clinical Pipeline by Mechanism of Action, 2010

Figure 9: Bronchitis Market - Clinical Pipeline by Phase of Development, 2010

Figure 10: Implications for Future Market Competition in the bronchitis Market, 2010

Figure 11: Bronchitis Disease Market - Clinical Pipeline by Company, 2010

Figure 12: GlobalData Methodology, 2010

Figure 13: GlobalData Market Forecasting Model, 2010